Aktien Sensor

AstraZeneca’s biotech portfolio continues to deliver significant milestones, including EU approval for a new treatment, positioning the company for long-term growth and value creation.

AstraZeneca is under investigation for potential securities fraud and unlawful business practices, and is also facing lawsuits from investors who claim the company made false statements.

AstraZeneca’s latest earnings report shows a 21% revenue increase and 19% rise in core earnings per share, driving the company’s shares to surge and solidifying its position as a leader in the pharmaceutical industry.